How decades of sleep research led to a new sleep apnea drug

[VUBot]

University of Toronto researcher Richard Horner’s work on sleep and breathing helped identify two key pathways that contribute to obstructive sleep apnea. Those findings helped lay the groundwork for AD109, a daily oral medication that showed positive results in a phase 3 randomized trial, with fewer breathing interruptions and higher oxygen levels than placebo. [temertymedicine.utoronto.ca]

Continue reading...